Amundi Trims Position in AtriCure, Inc. (NASDAQ:ATRC)

Amundi trimmed its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 270,455 shares of the medical device company's stock after selling 31,393 shares during the period. Amundi owned 0.55% of AtriCure worth $9,104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in ATRC. Heck Capital Advisors LLC bought a new stake in shares of AtriCure in the fourth quarter valued at approximately $60,000. Venturi Wealth Management LLC raised its holdings in AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after acquiring an additional 2,100 shares during the period. KBC Group NV lifted its position in shares of AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after acquiring an additional 932 shares in the last quarter. R Squared Ltd bought a new position in shares of AtriCure in the fourth quarter worth $89,000. Finally, M&T Bank Corp bought a new position in shares of AtriCure in the fourth quarter worth $208,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

ATRC has been the subject of a number of recent analyst reports. Oppenheimer lifted their target price on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Stifel Nicolaus lifted their price target on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Needham & Company LLC reiterated a "buy" rating and set a $51.00 target price on shares of AtriCure in a research report on Thursday, February 13th. Piper Sandler increased their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Finally, Canaccord Genuity Group raised their price objective on shares of AtriCure from $61.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.56.

Remove Ads

Insider Activity

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.20% of the company's stock.

AtriCure Trading Up 0.4 %

NASDAQ:ATRC traded up $0.15 during trading hours on Tuesday, reaching $33.93. The company's stock had a trading volume of 412,464 shares, compared to its average volume of 662,365. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -35.72 and a beta of 1.53. The firm has a 50-day simple moving average of $38.11 and a 200-day simple moving average of $33.54. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.